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Abstract
Objectives. Humanised mice have emerged as valuable models for
pre-clinical testing of the safety and efficacy of immunotherapies.
Given the variety of models available, selection of the most
appropriate humanised mouse model is critical in study design. Here,
we aimed to develop a model for predicting cytokine release
syndrome (CRS) while minimising graft-versus-host disease (GvHD).
Methods. To overcome donor-induced variation, we directly
compared the in vitro and in vivo immune phenotype of
immunodeficient NSG mice reconstituted with human bone marrow
(BM) CD34+ haematopoietic stem cells (HSCs), peripheral blood
mononuclear cells (PBMCs) or spleen mononuclear cells (SPMCs) from
the same human donors. SPMC engraftment in NSG-dKOmice, which
lack MHC class I and II, was also evaluated as a strategy to limit GvHD.
Another group of mice was engrafted with umbilical cord blood
(UCB) CD34+ HSCs. Induction of CRS in vivo was investigated upon
administration of the anti-CD3 monoclonal antibody OKT3. Results.
PBMC- and SPMC-reconstituted NSG mice showed short-term
survival, with engrafted human T cells exhibiting mostly an effector
memory phenotype. Survival in SPMC-reconstituted NSG-dKO mice
was significantly longer. Conversely, both BM and UCB-HSC models
showed longer survival, without demonstrable GvHD and a more
na€ıve T-cell phenotype. PBMC- and SPMC-reconstituted mice, but not
BM-HSC or UCB-HSC mice, experienced severe clinical signs of CRS
upon administration of OKT3. Conclusion. PBMC- and SPMC-
reconstituted NSG mice better predict OKT3-mediated CRS. The
SPMC model allows generation of large experimental groups, and
the use of NSG-dKOmicemitigates the limitation of early GvHD.
Keywords: animal models, cytokine release syndrome, humanized
mice, immune system, immunotherapy, pre-clinical safety
assessment
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INTRODUCTION
Great advances have been made in the
development of new therapeutic modalities that
target the human immune system in different
scenarios.1,2 However, these immunotherapies can
lead to severe and undesired adverse effects, and
effective pre-clinical animal models are essential
for safety and efficacy evaluation before
transition into clinical trials. Traditionally,
toxicology studies rely on the evaluation of
human biologics in non-human primates and of
surrogates in rodents.3 However, due to
evolutionary divergence, animal models may not
always predict toxicity in humans and could lead
to the induction of cytokine release syndrome
(CRS). CRS is a life-threatening systemic
inflammatory response, resulting from a massive
release of cytokines from targeted and bystander
immune cells, which in extreme cases can lead to
multiorgan failure.4–6 An unfortunate example is
TGN1412, an anti-CD28 superagonistic monoclonal
antibody (mAb). Pre-clinical testing of TGN1412
in vitro, in rodents with a surrogate and in
cynomolgus monkeys with the drug candidate,
was well tolerated with no sign of CRS.
Nonetheless, in the first-in-human trial
unexpected severe toxicity occurred, with
development of CRS and lymphopenia,6 which
was subsequently attributed to inter-species
differences in the expression of CD28 on CD4+
effector memory T cells.7,8 Similarly, muromonab
(OKT3), a murine anti-CD3 mAb that was
developed to treat acute rejection after organ
transplantation, led to CRS in patients, with
increased plasma levels of TNF-a, IFN-c and IL-2,
detected 1–2 h after administration. Moreover, at
this time point lymphocyte counts in blood
circulation had dropped in treated patients, and
lymphopenia persisted for more than 24 h.9,10
Immunodeficient mice reconstituted with
human immune cells, or humanised mice, are
emerging as valuable in vivo models to
investigate human immune responses. Several
different humanised mouse models have recently
been developed as pre-clinical models in
translational research.11–15 The most common
background strain of immunodeficient mice used
to achieve efficient levels of humanisation is NOD-
scid IL2Rcnull (NSG). These mice lack murine T, B
and natural killer (NK) cells, have defective
dendritic cells and macrophages, and impaired
innate immunity.16,17
The reconstitution of immunodeficient mice
with mature human peripheral blood
mononuclear cells (PBMCs) is one of the easiest
methods of humanisation and was first described
by Mosier et al. in 1988.18 This model allows the
examination of the human immune response
without delay in engraftment, as the human
leukocytes transferred into the mice are already
mature. Human T cells with a memory and
activated phenotype are predominantly present in
these humanised mice.11,12 However, the main
disadvantage of this model is the early
development of graft-versus-host disease (GvHD)
at four to eight weeks post-engraftment, most
likely triggered by the recognition of murine
antigens by the human lymphocytes. This
xenogenic immune response effectively reduces
the experimental window, so that only short-term
experiments are feasible.19 Longer experimental
windows may be possible with a new strain of
NSG mice deficient in the murine major
histocompatibility complex (MHC) class I and II
(NSG-dKO mice), which show increased survival
after PBMC humanisation and delayed GvHD.20
Alternatively, immunodeficient mice can be
reconstituted with human haematopoietic stem
cells (HSCs), obtained from either umbilical cord
blood (UCB),21 bone marrow (BM),22,23 foetal
liver23 or cytokine-mobilised from the BM into the
peripheral blood.24 HSC-reconstitution of
humanised mice leads to the generation of
multiple lineages of human immune cells and
survival of mice for more than 20 weeks. The
main caveats of these models are the time taken
to de novo generate human immune cells and
achieve stable human engraftment in mice,
together with the lack of a fully functional
human immune system, as most of the T, B, NK
cells and monocytes engrafted display some
impaired responses to antigens.25–27 To overcome
this disadvantage, transgenic mouse strains that
express human cytokines or specific HLA types
have been developed.28–32
Taken together, there are various humanised
mouse models that potentially could better
predict human immunotherapy toxicities. Several
studies have recently used these models to study
CRS induction after immunotherapy treatment.33–37
However, each of these models has a number of
limitations that first need to be better
understood. The biological variation between
human donors and the limited per-donor
availability of immune cells can lead to small
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experimental groups, which is a major cofounder
in many studies utilising humanised mouse
models. In this study, we characterise and
compare head-to-head the human immune
engraftment and survival of humanised mice
generated by reconstitution with either human
PBMCs, spleen mononuclear cells (SPMCs), UCB-
derived CD34+ HSCs or BM-derived CD34+ HSCs, to
elucidate the advantages and limitations of each
model to predict CRS. To avoid donor-related
variation, we used PBMCs, SPMCs and BM-HSCs
from the same donors for human immune
reconstitution in mice. We demonstrate, for the
first time, the potential of SPMCs derived from
deceased human organ donors for the generation
of large numbers of humanised mice and that
GvHD can be ameliorated by reconstitution of
NSG-dKO mice with SPMCs. We further show that
the PBMC and SPMC models, but not BM-HSC and
UCB-HSC models, develop CRS upon treatment
with OKT3 in vivo.
RESULTS
Survival and immune reconstitution
patterns in the different humanised mouse
models
We compared the survival and human immune
phenotype of humanised mice generated by
reconstitution of irradiated immunodeficient NSG
or NSG-dKO mice, with either human PBMCs,
SPMCs, BM-HSCs or UCB-HSCs, as represented in
Figure 1a. The donor demographics are shown in
Supplementary table 1.
NSG mice in the PBMC and SPMC models had a
similar short survival and needed to be sacrificed
between week 3 and 9 after immune reconstitution,
due to early development of GvHD (Figure 1b). In
comparison, survival of NSG-dKO20 mice
reconstituted with SPMCs from the same donor was
significantly extended, with five out of six mice alive
16 weeks after reconstitution and three mice
surviving to study end (week 20) without clinical
signs of GvHD (Figure 1b). In contrast, all NSG mice
in the BM-HSC and UCB-HSC models survived long
term, without signs of ill-health until the end of the
study at week 20 (Figure 1b).
Low levels of hCD45+ cells circulating in mouse
blood were detected one week after human
immune reconstitution in the PBMC and SPMC
models (< 3%), and increased steadily until the
experiment endpoint, which indicated human
leukocyte expansion in mice (Figure 1c). Of note,
the human subpopulations of hCD45+ cells
circulating in blood were predominantly (> 90%)
hCD3+ T cells (Figure 1d), with minimal hCD19+ B
cells (Figure 1e) and hCD14+ monocytes
(Supplementary figure 1) from the second week
post-engraftment. We observed significantly
slower engraftment kinetics in SPMC-reconstituted
NSG-dKO mice compared to NSG mice, with low
levels of hCD45+ cells in blood during weeks 1 to 4
(< 6%), which peaked after 9 weeks (~41%) and
then decreased to stable levels of 5–12% until the
experiment endpoint (Figure 1c). Importantly,
expansion of hCD3+ T cells was significantly
retarded in NSG-dKO mice, at levels of ~80%
during the first 4 weeks (Figure 1d), accompanied
by significant higher levels of hCD19+ B cells (15-
20%) compared to NSG mice during the same time
(Figure 1e).
Levels of hCD45+ cells in the BM-HSC model
increased from week 4, peaked at weeks 8–10 and
then decreased to stable levels of 6–10% until the
experiment endpoint (Figure 1c). In the UCB-HSC
model, de novo generated hCD45+ were found at
low levels in circulating blood 4 weeks after
reconstitution, followed by a rapid increase to a
plateau from week 8–10 onwards (~55%)
(Figure 1c). hCD19+ B cells were the predominant
(> 70%) subpopulation of hCD45+ cells in blood in
the BM-HSC and UCB-HSC models from week 4
(Figure 1e). In contrast, hCD3+ T cells were only
detected from week 10-12 (Figure 1d). hCD3+ T-
cell levels continued to increase steadily over
time, reaching constant levels of 15–20% within
hCD45 population by weeks 18–20. Importantly,
hCD14+ monocytes were found circulating in
mouse blood at low levels, 1–2% of hCD45+
throughout the experiment (Supplementary figure
1), supporting the multilineage haematopoietic
development of HSC models38.
Differential infiltration of mouse organs
with human cells across models
On flow cytometric assessment, the spleen was
the most efficiently repopulated lymphoid tissue
across all models, containing a higher proportion
of human cells than in circulating blood.
Accordingly, hCD45+ cell levels in the spleen of
PBMC- and SPMC-reconstituted NSG mice were
> 80% of total hCD45+cells, whereas this was
approximately 35% in SPMC engrafted NSG-dKO
mice and in BM-HSC mice, and 58% in UCB-HSC
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Figure 1. Distinct survival and human reconstitution in the different humanised mouse models. (a) Schematic representation of the generation
of different humanised mouse models. To prevent donor-related variations, PBMCs, SPMCs and BM-HSCs used for reconstitution of NSG mice,
were isolated from the same three adult donors (Donors 1–3). For the SPMC dKO model, NSG-dKO mice were humanised with SPMCs from
Donor 3. For the UCB-HSC model, NSG mice were reconstituted with UCB-HSCs cells from Donor 4. (b) Kaplan–Meier plot showing overall
survival of the different humanised mouse models. Mice were sacrificed at 20 weeks or earlier if they showed clinical signs of GvHD. (c) Levels of
hCD45+ cells circulating in PB of mice at the indicated time points. (d) Levels of hCD3+ T cells and (e) hCD19+ B cells circulating in PB of mice.
Data in the PBMC (n = 14), SPMC (n = 17) and BM-HSC (n = 13) models are representative of three independent experiments with Donors 1–3
in each model. Data in the SPMC dKO model (n = 6) are representative of one experiment with Donor 3. Data in the UCB-HSC (n = 7) are
representative of one experiment with Donor 4. Data are mean  SEM. The Mantel–Cox test was used to assess statistical differences between
models in b, and a two-way ANOVA to assess differences at each time point between models in c–e; *P < 0.05, **P < 0.01, ***P < 0.001. BM-
HSC, bone marrow haematopoietic stem cells; i.p., intraperitoneally; i.v., intravenously; NSG, NOD scid gamma; NSG-dKO, NOD scid gamma
double knockout; PB, peripheral blood; PBMC, peripheral blood mononuclear cells; SPMC dKO, SPMC model in NSG-dKO mice; SPMC, spleen
mononuclear cells; UCB-HSC, umbilical cord blood haematopoietic stem cells.
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mice (Supplementary figure 2). In addition,
human cell engraftment in the bone marrow of
mice was greater in BM-HSC and UCB-HSC models
than in PBMC and SPMC models (~28% and 58%
vs ~13% and 20%, respectively), demonstrating a
niche-like migration of human HSC cells
(Supplementary figure 2).
PBMC- and SPMC-reconstituted NSG mice
showed substantial immune cell infiltration of all
tissues examined on immunohistochemistry (IHC)
(Figure 2 and Supplementary figure 3). The spleen
was the most extensively infiltrated organ,
consistent with flow cytometry data. There was
expansion of the splenic white pulp periarteriolar
lymphoid sheath areas, infiltrated with hCD45+
cells. The liver showed changes indicative of
hepatitis, with infiltration of hCD45+ immune cells
around centrolobular veins and in the portal areas
and periportal lobular parenchyma, associated with
necrosis of single hepatocytes. The percentage of
hCD45+ area in this organ was ~5–7% (Figure 2).
There was also considerable infiltration of hCD45+
immune cells in the lungs (~19–23% hCD45+ area),
with cells accumulating around blood vessels and
airways, and extending into the alveolar
interstitium (Supplementary figure 3). The kidneys
also showed infiltration by hCD45+ cells (~2–5%
hCD45+ area), predominantly under the pelvic
epithelium and around cortical blood vessels
(Supplementary figure 3). These findings are
considered consistent with manifestations of GvHD,
mediated by hCD45+ immune cells. The histological
patterns and the overall severity of the of immune
cell infiltration were similar between the PBMC and
SPMC models.
In contrast, SPMC-reconstituted NSG-dKO mice
that survived to the study endpoint (20 weeks),
and NSG mice in the BM-HSC and UCB-HSC
models, only showed histologically visible changes
in the spleen, with a mild degree of splenic white
pulp expansion by hCD45+ cells (Figure 2). Small
numbers of hCD45+ cells (< 1% hCD45+ area) were
scattered throughout the liver, lung and kidney,
but without substantial aggregation or evidence
of GvHD-type inflammatory lesions (Figure 2 and
Supplementary figure 3).
Phenotypic characterisation of engrafted
human leucocytes in humanised mouse
models
Immunophenotyping of hCD45+ cells engrafted in
mice, revealed a prominent infiltration of hCD3+ T
cells (> 85%) in the spleen of PBMC- and SPMC-
reconstituted NSG or NSG-dKO mice (Figure 3a).
Fewer hCD19+ B cells were present in the PBMC
model (~2%) than in the SPMC model with NSG
mice (~8%), or with NSG-dKO mice (~13%)
(Figure 3a and Supplementary figure 4a). As
expected12, engraftment of other human cell
lineages in the spleen of mice, including
monocytes, macrophages, NKs and dendritic cells
was substantially lower (<0.6%) in these models
(Figure 3a and Supplementary figure 4a),
although they were a component of the initial
PBMCs and SPMCs inoculums (Supplementary
figure 5a, b). In contrast, BM-HSC and UCB-HSC
models showed a diverse repertoire of human
immune populations engrafting the spleen at
sacrifice (Figure 3a). A significantly higher
proportion of hCD19+ B cells was found in these
models (BM-HSC ~ 49%; UCB-HSC ~ 76%),
together with a significantly lower percentage of
hCD3+ T cells (BM-HSC ~ 48%; UCB-HSC ~ 20%)
and higher levels of myeloid cells (Figure 3a and
Supplementary figure 4a).
The majority (> 90%) of hCD3+ T cells in the
PBMC- and SPMC-reconstituted NSG or NSG-dKO
mice exhibited a memory phenotype (Figure 3b),
suggesting xeno-activation of transferred hCD3+ T
cells from the initial inoculums (Supplementary
figure 5c). In comparison, a significantly lower
percentage of hCD3+ memory cells was found in
the BM-HSC and UCB-HSC models (47–56%), along
with a higher proportion of hCD3+ na€ıve cells (34–
42%) (Figure 3b). The hCD4:hCD8 ratio in the
spleen of PBMC and SPMC NSG mice was ~1:1.5
(Supplementary figure 4b), similar to that in the
original human donor samples (Supplementary
figure 5d). In contrast, in SPMC-reconstituted NSG-
dKO mice the ratio was ~4:1 (Supplementary
figure 4b), demonstrating an increased expansion
of hCD4+ cells in these mice. A hCD4:hCD8 ratio of
~1:1.2 was detected in BM-HSC mice and of ~1.2:1
in UCB-HSC mice (Supplementary figure 4b).
hCD4+ T cells in these latter models showed a
significantly lower percentage of Th1 cells
(< 45%), and a more diverse range of hCD4+
subpopulations than in the PBMC- and SPMC-
reconstituted NSG or NSG-dKO mice, where the
majority (> 90%) of hCD4+ T cells showed a Th1
phenotype (Figure 3c and Supplementary figure
4c). The same pattern was observed within hCD8+
T cells among all models (Supplementary figure
4d). Interestingly, hCD4+ Tregs were found at
levels of 3-5% in all mouse models
ª 2020 The Authors. Clinical & Translational Immunology published by John Wiley & Sons Australia, Ltd on behalf of
Australian and New Zealand Society for Immunology, Inc.
2020 | Vol. 9 | e1202
Page 5
A Matas-Cespedes et al. Humanised mice for immunotherapy testing
(Supplementary figure 4c), which was similar to
the levels present in the original donor PBMC and
SPMC samples (2–3%) (Supplementary figure 5e).
The majority of hCD4+ and hCD8+ cells expressed
the activation marker PD-1 in the PBMC- and
SPMC-reconstituted NSG or NSG-dKO mice, but
the expression was significantly lower in the BM-
HSC and UCB-HSC models (Figure 3d).
At termination, the immunophenotype of























Figure 2. Histological comparison of human immune cell infiltration and inflammation levels in mouse tissue. Representative images of the H&E
and hCD45 staining on the spleen and liver of one mouse in each model, reconstituted with Donor 3 (PBMC, SPMC, SPMC dKO and BM-HSC
models) and Donor 4 (UCB-HSC model). PBMC and SPMC mice shown were sacrificed at week 5 and 6, after GvHD development. SPMC dKO,
BM-HSC and UCB-HSC mice shown were sacrificed at study end at week 20. Magnification: 9400 for the liver and 9200 for the spleen. BM-
HSC, bone marrow haematopoietic stem cells; H&E, haematoxylin and eosin; PBMC, peripheral blood mononuclear cells; SPMC dKO, SPMC
model in NSG double knockout mice; SPMC, spleen mononuclear cells; UCB-HSC, umbilical cord blood haematopoietic stem cells.
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Figure 3. Immunophenotyping of hCD45+ cells infiltrating the spleen of the different humanised mouse models. (a) Visualisation using t-SNE (t-
stochastic neighbour embedding) of immune subpopulations within hCD45+ cells infiltrating the spleen of one representative mouse in each model
(Donors 3 and 4) at sacrifice analysed by flow cytometry. (b) Percentage of memory phenotype on hCD3+ T cells infiltrating the spleen of mice. (c)
Representative data of hCD4+ T helper cell subtypes and their proportions of the whole hCD4+ population. Mean of all donors combined is shown
in b and c. (d) Expression of PD-1 on hCD4+ and hCD8+ T cells. Histograms are representative of one mouse in each model (Donors 3 and 4).
Relative PD-1 expression on hCD4+ and hCD8+ T cells in the spleen of mice. The MFI is plotted as a relative fold difference as compared to the FMO
controls. Mean  SD are shown. Mice and donor numbers are the same as in Figure 1. A two-way ANOVA was used to determine significant
differences between models; *P < 0.05, **P < 0.01, ***P < 0.001. BM-HSC, bone marrow haematopoietic stem cells; FMO, fluorescence minus
one; MFI, mean fluorescence intensity; NK, natural killer; PBMC, peripheral blood mononuclear cells; SPMC dKO, SPMC model in NSG double
knockout mice; SPMC, spleen mononuclear cells; TFH, T follicular helper; UCB-HSC, umbilical cord blood haematopoietic stem cells.
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the spleen of humanised mice across models was
comparable, with similar distribution of hCD45+
subpopulations (Supplementary figure 6a) and
human T-cell immunophenotype (Supplementary
figure 6b–g).
Impaired human CD3+ T-cell function
in vitro after engraftment in mice
Activation and cytokine release by hCD3+ T cells is
thought to be critical for CRS induction. To
determine the functionality of hCD3+ T cells
engrafted in the spleen of different humanised
mouse models, we first evaluated their ability
in vitro to produce cytokines, accompanied by
activation and proliferation. Similar to pre-
engraftment human PBMCs and SPMCs inoculums
(Figure 4a), hCD3+ T cells isolated from the spleen
of humanised mice produced intracellular TNF-a in
all models after co-culture with CD3/CD28 beads
(2.5–7.5%) (Figure 4b, left). A significant increase
in intracellular IFN-c was also observed in the
PBMC, SPMC and UCB-HSC models after this
stimulus (Figure 4b, right). In contrast, stimulation
with OKT3 induced only low levels of cytokine
production on hCD3+ T cells post-engraftment in
mice, with a modest increase in TNF-a only in the
UCB-HSC model and of IFN-c in the SPMC
engrafted NSG mice (Figure 4b). These results
demonstrate that hCD3+ T cells derived from the
spleen of humanised mice can still induce cytokine
secretion in vitro, but mainly after strong
stimulation with the CD3/CD28 beads.
Furthermore, we observed a slightly increased IFN-
c production rather than TNF-a in the hCD3+ T
cells derived from PBMC and SPMC engrafted
mice, while a greater TNF-a production was
detected in the original PBMCs and SPMCs
(Figure 4a).
Similar to the activation and proliferation levels
of human PBMCs and SPMCs inoculums
(Figure 5a, b), > 70% of hCD3+ T cells isolated
from mouse spleen showed significant levels of
CD25 expression, indicative of an activated
phenotype, after incubation with CD3/CD28 beads
(Figure 5c). This activation was accompanied by a
substantial increase in proliferating hCD3+ T cells
(> 17%) in the PBMC and SPMC models compared
to their controls (Figure 5d). Similar to the
cytokine release, stimulation with OKT3 resulted
in less activation of hCD3+ T cells (Figure 5c),
together with reduced proliferation levels in all
models (Figure 5d).
Only PBMC and SPMC humanised mice
recapitulate OKT3-induced cytokine release
syndrome (CRS)
We next compared the effect of i.v. OKT3
administration and the induction of CRS in the
different humanised mouse models generated
using cells from the same donors, as detailed in
Figure 6a. NSG mice in the PBMC and SPMC
models and SPMC engrafted NSG-dKO mice
rapidly exhibited clinical signs of ill-health after
OKT3 treatment, showing impaired mobility,
hunched posture, piloerection and a drop in body
temperature detectable as soon as 1h post
injection and progressively worsening until the
time of sacrifice at 6h (T ~ 32°C). In contrast,
OKT3-treated mice in the BM-HSC and UCB-HSC
models did not display any adverse signs and their
temperature remained stable (T ~ 35.5°C)
(Figure 6b). Nevertheless, treatment with OKT3
induced lymphopenia, as evidenced by a marked
reduction in hCD45+ peripheral blood cells in all
humanised mouse models (Supplementary figure
8a), with a selective hCD3+ T-cell loss from
peripheral blood and a complete downregulation
of hCD3+ expression (Figure 6c), as reported in
patients.9,10 Furthermore, fewer hCD4+ and hCD8+
T cells remained in circulating blood in all models
after OKT3 treatment, but with downregulated
human TCR/CD3 complex (Supplementary figure
8b–f), as previously reported in humans.39,40
We also detected by IHC, reduced expression of
hCD3+ T cells in spleen and lungs of OKT3-treated
mice, compared to the group administered with
PBS (Figure 6d and Supplementary figure 9a),
indicating that OKT3 had efficiently reached these
organs. Following further analysis of the spleen
by flow cytometry, we corroborated a complete
downregulation of the human TCR/CD3 complex
in OKT3-treated groups, while the percentage of
hCD4+ and hCD8+ T cells remained unchanged
compared to controls (Supplementary figure 10a-
e). These data confirmed that hCD3+ T cells were
not depleted by OKT3, but rather the human TCR/
CD3 complex was downregulated, consistent with
the mode of action of OKT3.39,40
Finally, a different pattern of cytokine secretion
was uncovered in plasma across humanised mouse
models upon OKT3 treatment. As shown in
Figure 6e, higher levels of human IL10, TNF and
IFN-c were released in PBMC, SPMC and SPMC-
NSG-dKO mice compared to BM-HSC and UCB-HSC
mice. In contrast, IL-2 was similarly secreted in
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PBMC, SPMC, SPMC dKO and UCB-HSC mice. OKT3
also induced some release of IL-4, IL-6 and IL-17A,
but to considerably lower absolute levels in all
models (Supplementary figure 9b).
DISCUSSION
Humanised mice are increasingly recognised as
promising models in translational research
permitting the investigation of human immune
responses in different scenarios.14,38,41 However,
due to the great variety of humanised mouse
models available, the choice of the most
appropriate model should be made in accordance
with the research question to address. In the
present work, we report for the first time a
detailed comparison of the different humanised
mouse models generated by reconstitution with
human cells from the same donors, to reduce
donor-related variations.























































































































































Figure 4. Intracellular cytokine production by human T cells pre- and post-engraftment in mice. (a) Intracellular cytokine production by Hu-
PBMCs (n = 2) and Hu-SPMCs (n = 3) samples before engraftment into mice, after 24 h of culture in vitro. The percentage of TNF-a (left panel)
and IFN-c (right panel) positive hCD3+ T cells is shown. Data from three independent experiments with Donors 1–3 are represented. (b)
Intracellular cytokine production by human lymphocytes isolated from the spleen of humanised mice at the experiment endpoint, after 24 h of
culture in vitro. For the PBMC (n = 4–9), SPMC (n = 6–12) and the BM-HSC (n = 3–7) models, data from three independent experiments with
Donors 1–3 in each model are shown. In the SPMC dKO model (n = 3–5) data are representative of one experiment with Donor 3. In the UCB-
HSC model (n = 7) data are representative of one experiment with Donor 4. Individual data and mean  SD of all donors combined are shown.
The non-paired t-test and two-way ANOVA were used to determine significant differences between control and treated groups in each model;
*P < 0.05, **P < 0.01, ***P < 0.001. BM-HSC, bone marrow haematopoietic stem cells; Hu-PBMCs, human PBMCs inoculum; Hu-SPMCs,
human SPMCs inoculum; PBMC, peripheral blood mononuclear cells; SPMC, spleen mononuclear cells; SPMC dKO, SPMC model in NSG double
knockout mice; UCB-HSC, umbilical cord blood haematopoietic stem cells.
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Our results represent a first proof of concept
that effective humanisation can be achieved after
reconstitution of mice with SPMCs isolated from
the spleen of human organ donors. Much higher
numbers of lymphocytes (~1 9 1010–11; data not
shown) can be isolated from a human spleen
compared to a peripheral blood sample.
Therefore, it is possible to generate substantially
larger groups of humanised mice from SPMCs,
thus enabling experiments to be repeated using
the same donor material. Of note, the lymphocyte
distribution in the human spleen is different to
that in the peripheral blood, containing more B
cells than T cells and a greater number of
activated T cells with memory phenotype
(Supplementary figure 5a–c), in agreement with
the important role of the spleen in the immune
cell homeostasis and induction of systemic
immune responses.42,43 Despite these phenotypic
differences, we observed a similarly short survival
in NSG mice reconstituted with either SPMCs or
PBMCs, due to early development of GvHD. In
both models, a predominant human T-cell
expansion was observed over time, with an


















































































































Figure 5. Activation and proliferation of human T cells pre- and post-engraftment in mice. (a) Percentage of activated hCD3+ T cells (CD25+)
and (b) proliferating hCD3+ T cells (CFSELow) in Hu-PBMCs and Hu-SPMCs samples before engraftment into mice, after 72 h of in vitro culture.
Data of three independent experiments with Donors 1–3 are shown. (c) Percentage of activated hCD3+ T cells (CD25+) and (d) proliferating
hCD3+ T cells (CFSELow) isolated from the spleen of humanised mice at the experiment endpoint, after 72 h of in vitro culture. Mice and donor
numbers are the same as in Figure 4b. Individual data and mean  SD of all donors combined are shown. The non-paired t-test and two-way
ANOVA were used to determine significant differences between control and treated groups in each model; *P < 0.05, **P < 0.01, ***P < 0.001.
BM-HSC, bone marrow haematopoietic stem cells; Hu-PBMCs, human PBMCs inoculum; Hu-SPMCs, human SPMCs inoculum; PBMC, peripheral
blood mononuclear cells; SPMC dKO, SPMC model in NSG double knockout mice; SPMC, spleen mononuclear cells; UCB-HSC, umbilical cord
blood haematopoietic stem cells.
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activated memory phenotype constituting mostly
Th1 and Tc1 subtypes. Although other human cell
subpopulations were present in the initial PBMC
and SPMC inoculums, the major expansion of T
cells in the murine environment and the lack of
human specific cytokines needed, might impair
their survival.44,45 Nonetheless, the observed
higher number of hCD19+ B cells infiltrating the
spleen of mice in the SPMC model compared to
the PBMC model could be attributed to the
higher percentage of hCD19+ B cells in the initial
SPMCs inoculum, which are likely to express
chemokine receptors for homing to the spleen of
mice. Overall, the repopulation capacity of human
cells was comparable across PBMC and SPMC
models, with human leucocytes present in all
mouse organs examined and with inflammation
of similar severity.
A major limitation that arises in the PBMC and
SPMC models is the early development of GvHD,
which reduces the available experimental
window. This xenogeneic reaction is thought to
be mainly due to the recognition of the murine
MHC antigens by human T cells, inducing their
subsequent activation and expansion.19 Hence, to
overcome this short-term survival, we engrafted
human SPMCs into NSG-dKO mice, which lack
murine MHC class I and II.20 The overall survival
was significantly extended in most of NSG-dKO
mice beyond 16 weeks, in comparison to NSG
mice engrafted with SPMCs from the same donor,
which developed GvHD within 7 weeks. Human
CD45+ cells were found in circulating blood of
NSG-dKO mice one week after humanisation, but
with a significantly slower T-cell expansion
kinetics. This is consistent with a reduced xeno-
activation of human T cells that results in a lower
expansion and reactivity to the mouse
environment. Interestingly, hCD3+ T cells in NSG-
dKO mice at sacrifice had a T memory phenotype,
with high expression of the activation marker PD-
1, as previously reported by Brehm et al.20 This
suggests that despite the lack of murine MHC
class I and II molecules, which are the major
targets of the xeno-response, there are other
xeno-antigens that activate human T cells in these
mouse models and can lead to GvHD development
over time.20 Nevertheless, this activation was
slower than in NSG mice, allowing the favorable
expansion of hCD4+ T cells with better tolerance
to the host. The number of hCD8+ T cells, which
are the most potent effectors mediating GvHD,46
was also lower than in NSG mice. The reduced T-
cell expansion was corroborated by a lower
infiltration of hCD45+ cells in solid organs in NSG-
dKO mice and the absence of inflammatory
lesions in those mice that survived until the study
end.
In contrast, HSC reconstituted mice experienced
a de novo generation of multiple human cell
populations differentiated in mouse environment,
with a stable human repopulation from week 18
onwards. We observed significantly greater
generation of human leucocytes in mice
reconstituted with HSC cells derived from UCB
than in mice reconstituted with adult BM-HSCs, in
accordance with a major pluripotent capacity
retained in UCB-HSCs than in adult HSCs.23,47 Due
to this more persistent and robust human
engraftment, UCB samples are commonly the
source of choice by many research groups for HSC
transplantation in mice. Despite the differences in
engraftment, the infiltration of human leucocytes
in mouse tissues was comparable between BM-
HSC and UCB-HSC models, with T cells, B cells, NK
cells and myeloid cells in similar proportions.
These mice survived for more than 20 weeks
without development of GvHD. The absence of
GvHD can be explained by the negative selection
that human HSCs undergo during differentiation
in the mouse environment, making these human
cells more tolerant to mouse-derived antigens and
with higher activation thresholds26,27.
The in vitro evaluation of human T-cell activity
in humanised mice demonstrated an impaired
hCD3+ T-cell function in all models and the need
for a strong stimulation to be responsive, in
comparison to the cytokine production and
proliferation levels achieved on human T cells pre-
engraftment. In the HSC models, this impairment
of T-cell function in vitro had been previously
reported25,26 and could be attributed to an
anergic state of these cells in mice, due to the
limited education of human T cells during their
haematopoiesis on mouse MHC molecules,
together with the lack of human cytokines
needed to develop a fully functional human
immune system. Conversely, in the PBMC and
SPMC models in NSG mice, the rapid activation
and expansion of human T cells in response to the
xeno-reactive mouse environment, could lead to
T-cell exhaustion over time. This phenomenon
may be the consequence of a protracted T-cell
response, where T-cell stimulation continues as
the antigen cannot be cleared.48 In these models,
stimulation of mouse-derived hCD3+ T cells
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Australian and New Zealand Society for Immunology, Inc.
2020 | Vol. 9 | e1202
Page 11



















Blood FC and plasma






















T before T sacrifice


























































Figure 6. Response to OKT3 treatment in different humanised mouse models. (a) Experimental design to evaluate induction of cytokine release
syndrome in humanised mice. (b) Body temperature (°C) of OKT3-treated mice before and 6 h after treatment. The paired t-test was used to
determine significant differences before-after OKT3 treatment. (c) Number of hCD3+ T cells per lL of mouse blood assessed before and 6 h after
OKT3 treatment. (d) Representative images of the hCD3+ T-cell staining of the spleen of one PBS and one OKT3-treated mouse in each model,
corresponding to mice reconstituted with Donors 4 (UCB-HSC model) and 5 (PBMC, SPMC and BM-HSC models), magnification 9200. For the
PBMC (n = 6 or 7), SPMC (n = 8 or 9) and the BM-HSC (n = 5 or 6) models, data from two independent experiments with Donors 5 and 6 in
each model are shown. Data in the NSG-dKO mice (n = 3–5) correspond to one experiment reconstituting with SPMCs cells from Donor 6. In the
UCB-HSC model (n = 6 or 7) data are representative of two independent experiments with Donor 4. Individual mouse data and mean  SD of all
donors combined are shown. The non-paired t-test was used to determine significant differences between PBS and OKT3 treated mice in each
model; *P < 0.05, **P < 0.01, ***P < 0.001. BM-HSC, bone marrow haematopoietic stem cells; FC, flow cytometry; IHC, immunohistochemistry;
NSG-dKO, NOD scid gamma double knock out; PBMC, peripheral blood mononuclear cells; SPMC dKO, SPMC model in NSG double knockout
mice; SPMC, spleen mononuclear cells; T, temperature; UCB-HSC, umbilical cord blood haematopoietic stem cells.
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in vitro with the anti-CD3 mAb OKT3, was not
sufficient to result in cytokine production,
activation and proliferation of hCD3+ T cells. In
contrast, incubation with CD3/CD28 beads, which
provide coupled stimulatory signals, achieved
cytokine production, activation and proliferation
of hCD3+ T cells post-engraftment, but to a lower
extent than that observed with the original
PBMCs and SPMCs samples. In addition, the shift
in the cytokine pattern towards IFN-c production
rather than TNF-a post-engraftment is consistent
with T-cell xeno-activation and exhaustion, as this
cytokine has a role in T-cell homeostasis limiting
the expansion of T cells especially after prolonged
antigen stimulation.48-51 The in vitro functionality
of hCD3+ T cells derived from NSG-dKO mice was
similar to NSG mice, with cells reacting and
achieving cytokine production, activation and
proliferation only after strong CD3/CD28
stimulation. Again, this relative anergy is likely
due to the prolonged exposure to the murine
environment, as NSG-dKO mice had a significant
longer survival than NSG after SPMCs
reconstitution. Collectively, these data suggest
that the human T cells isolated from humanised
mice require strong stimulation in vitro to be
rescued from their anergic state.
The in vivo comparison of CRS induction after
i.v. administration of OKT3 revealed different
responses across the humanised mouse models.
PBMC- and SPMC-reconstituted NSG mice,
together with SPMC NSG-dKO mice, manifested
severe adverse clinical signs and a significant drop
in body temperature early after treatment,
consistent with previous reports using PBMC-
reconstituted humanised mice.33,34,37 However,
BM-HSC and UCB-HSC mice did not exhibit any
symptoms of illness and their temperature
remained constant for the 6 hours of experiment.
Interestingly, all models demonstrated a marked
lymphopenia, with a significant loss of hCD3+ T
cells from circulation, as observed in patients.9,10
Furthermore, we found some remaining levels of
hCD4+ and hCD8+ T cells in circulation that did
not express either hCD3 nor TCRa/b, suggesting











































































Figure 6. (Continued). (e) Human cytokines secreted into mouse plasma evaluated in PBS and OKT3 treated mice at sacrifice.
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peripheral blood but those remaining had
downregulated TCR/CD3 complex. This mechanism
of action has been described for CD3-specific
antibodies after binding CD3, resulting in the
internalisation or capping of TCR/CD3 complex
from cell surface.40 This phenomenon was also
observed in spleen and lungs from OKT3-treated
mice. We did not find major changes in the
proportion of hCD4+ or hCD8+ T cells infiltrating
the spleen in OKT3-treated groups, compared to
their controls in any mouse model. This finding
was also reported by Weißm€uller et al.34 in lymph
nodes, thymus and peritoneum of humanised
mice, suggesting that human T cells cleared from
circulating blood did not migrate to solid organs
after treatment.
We detected a broad range of human cytokines
secreted in OKT3-treated mice in all models
compared to their controls, but a considerably
higher secretion in PBMC, SPMC and SPMC-NSG-
dKO mice. The pro-inflammatory cytokines known
to be highly released upon administration of
OKT3 in patients, TNF-a and IL-2, were detected at
lower concentrations in these models, probably
due to the reduced number of human cells in
these mice compared to humans.9,10 Nonetheless,
IFN-c levels were greatly increased in these
humanised mouse models,52 which may be a
consequence of the shift in the cytokine pattern
described above. Of note, the total number of
hCD3+ T cells circulating in mouse blood on the
day of the experiment was different across
models, as depicted in Figure 6c. However, these
differences did not correlate with a more severe
response to OKT3 and increased secretion of
cytokines. As demonstrated in the PBMC model,
although the average number of hCD3+ T cells in
circulation was lower than in the UCB-HSC model,
all the OKT3 treated mice in the PBMC model
suffered severe clinical signs accompanied by an
extensive secretion of human cytokines. In
addition, the intra-group variations on hCD3+ T-
cell numbers did not correlate with increases in
adverse effects in mice. Hence, the distinct
response to OKT3 may be attributed to the
different levels of maturation of hCD3+ T cells
across models. Our data are in accordance with
previous reports where OKT3 showed induction of
cytokine release on activated hCD3+ T cells but
not on na€ıve T cells.53 Hence, suggesting that the
limited education of hCD3+ T cells in the BM-HSC
and UCB-HSC models44,54 impaired their response
to OKT3 in vivo.
Interestingly, fever is one of the most common
symptoms of CRS in patients, due to the systemic
release of pro-inflammatory cytokines.4,5,9,10 In
contrast, PBMC, SPMC and SPMC-NSG-dKO
reconstituted mice, experienced a significant drop
in body temperature after OKT3 administration,
despite secreting human pro-inflammatory
cytokines. The mechanism underlying this effect is
not clear yet, and has also been reported by
others using these models to evaluate
therapeutic-related CRS.33,34,37 A possible
explanation is cytokine species-specificity, as the
human cytokines secreted are likely to have
differential effects in these mice, with their
cognate human receptors potentially only
expressed on engrafted cells, and signalling of
human cytokine through mouse cytokine
receptors probably limited.55 Thus, human IFN-c
which is highly secreted in PBMC and SPMC
models, does not cross-react with mouse
receptors.55,56 In contrast, human TNF-a is
potentially cross-reactive as it shares 78%
homology with its mouse counterpart.19,55
Moreover, both NSG and NSG-dKO mice have a
complete null mutation of the gamma chain of
the IL-2 receptor (IL2Rcnull),16 which is a common
component of the cell surface receptors of IL-2,
IL-4, IL-7, IL-9, IL-15 and IL-21. Hence, although
some of these human cytokines are cross-reactive
in mice, their signalling pathways are blocked.
However, other cytokines released by human T
cells upon OKT3 treatment, could also be involved
in the hypothermia and contribute to the rapid
development of symptoms in PBMC, SPMC and
SPMC-NSG-dKO humanised mouse models. Despite
these inter-species differences, the information
derived from the toxicity studies in the
aforementioned models, demonstrate that these
models recapitulated the side effect of OKT3
treatment in patients, including lymphopenia,
downregulation of the hTCR/CD3 complex and
CRS, secreting a wide range of cytokines.
Moreover, our data confirmed a similar in vivo
response to OKT3 between SPMC-reconstituted
NSG and NSG-dKO mice, with a significant longer
survival observed in NSG-dKO mice, allowing their
experimental use for a longer duration after
humanisation.
Humanised mice have been used by others to
evaluate CRS upon mAb treatment. In a recent
study, Ye et al.37 demonstrated the efficacy of
using PBMC-reconstituted NSG, NSG-dKO or NSG-
SGM3 (expressing hIL-3, GM-CSF and SCF) mice to
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evaluate the induction of CRS after OKT3,
TGN1412 analogue or Keytruda (anti-PD-1)
treatment. These models showed a rapid and
strong response, capturing the variation in CRS
between different donors and in a drug-
dependent manner, reproducing the response
observed in patients. Similarly, Weißm€uller et al.34
reported severe adverse reactions and CRS
induction after OKT3 or TGN1412 treatment of
PBMC-engrafted NRG or NRG HLA-DQ8 + Ab1null
transgenic mice. No differences in response
between non-transgenic and DQ transgenic mice
were detected, suggesting no benefit for an HLA-
DQ transgenic mouse in the PBMC model. The use
of a more sophisticated model, the NOG-BLT
(bone marrow-liver-thymus) model, where mice
develop a fully engrafted human immune system
has also been explored,35,36 with the advantage
that these mice could be more responsive to a
larger diversity of immunotherapies due to the
greater diversity of immune populations present.
However, the limited availability of human foetal
tissues is a major challenge in the development of
this model.
Collectively, our findings suggest that
humanised mouse models have the potential to
be valuable models for pre-clinical safety testing
of immunotherapies and can mimic several of the
severe adverse effects induced upon mAb
treatment in patients. However, careful selection
of the humanised mouse model is crucial, as we
have demonstrated that the distinct models are
incumbered by different limitations. These models
continue to evolve, adding more complexity and
overcoming deficiencies. Hence, as sophistication
raises, their utility will also likely grow. An
increasing interest in using these models for
efficacy evaluation of immune-oncology drugs has
also arisen in the last years. In this context, the
potential to establish primary tumors in
humanised mice reconstituted with a human
immune system, including from autologous




BM, peripheral blood and spleen samples were obtained
from deceased transplant organ donors after obtaining
informed consent from the donor families with full
ethical approval (15/EE/0152, NRES Committee East of
England – Cambridge South). Peripheral blood samples
were taken before the cessation of circulation. Spleen
and bone marrow samples were taken immediately after
the removal of organs for transplantation. BM was
aspirated from the thoracic and/or lumbar vertebrae of
deceased donors. Human UCB-derived CD34+ HSCs,
positively isolated via immunomagnetic separation with a
purity > 90%, were purchased from Lonza (Basel,
Switzerland). Donor characteristics are summarised in
Supplementary table 1.
For the human donor spleen, a single cell suspension was
prepared in RPMI-1640 (Gibco, Paisley, UK) supplemented
with 10% FBS (Gibco), following mechanical tissue
dissociation with the gentleMACSTM dissociator (Miltenyi
Biotec, Bergisch Gladbach, Germany) and filtration of the
cellular fraction through a 70-µM cell strainer (Corning, NY,
USA). For the human donor BM, the aspirated sample was
diluted in RPMI-1640 + 10% FBS and filtered through a 70-
µM cell strainer. Human donor peripheral blood was diluted
in RPMI-1640 + 10% FBS medium. Mononuclear cells were
isolated from the single cell suspension of the spleen, BM
or peripheral blood of the donors by gradient
centrifugation on LymphoprepTM (StemCell Technologies,
Vancouver, BC, Canada) at 800 g, for 20 min, at room
temperature (RT). Erythrocytes were lysed with red blood
cell lysis (RBCL) buffer when necessary. Mononuclear cells
were cryopreserved in liquid nitrogen in 90% FBS + 10%
DMSO and stored within the Department of Surgery for
future use.
Mice
NOD.Cg-PrkdcSCIDIl2rgtm1Wjl/SzJ (NSG) mice and NSG-
(KbDb)null (IA)null mice (referred to as NSG-double knockout:
NSG-dKO), were purchased from Charles River (Saffron
Walden, UK) and The Jackson Laboratory (Sacramento, CA,
USA) respectively, and used to set up breeding colonies that
were housed in individually ventilated cages and
maintained in a pathogen-free facility at the Central
Biomedical Services, University of Cambridge. All
experimental procedures were approved by the United
Kingdom Home Office under the Animal (Scientific
Procedures) Act 1986 (PPL 70/8702 and P57643EBB).
Immune reconstitution
For the PBMC and SPMC models, 6–8 week-old NSG or NSG-
dKO mice were weighed and irradiated at 2.3Gy using a
Caesium-137 source, 4–24 h before immune reconstitution.
Human PBMCs or SPMCs were defrosted, resuspended in
PBS + 2% FBS and 1 9 107 cells injected into each mouse
intraperitoneally (i.p.). Several SPMCs samples were
incubated after defrosting with 0.04 mg mL1 DNAse-I
(Sigma-Aldrich, St. Louis, MO, USA) at 37°C for 30 min, to
avoid clumping of cells.
For the BM-HSC model, 5–6-week-old NSG females were
weighed and irradiated at 2.5Gy using a Caesium-137
source, 4–24 h before immune reconstitution. Human BM-
derived HSCs were defrosted and depleted for hCD3+ cells
using anti-CD3 coated microbeads (Milteny Biotec, Bergisch
Gladbach, Germany), at a concentration recommended by
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the manufacturer, in the AutoMACS Pro Separator
(Milteny Biotec). The negative fraction was resuspended
after depletion in PBS + 2% FBS, and 1 9 107 cells injected
into each mouse intravenously (i.v.).
For the UCB-HSC model, 5–6-week-old NSG females were
weighed and irradiated at 2.5Gy using a Caesium-137
source, 4–24 h before the humanisation. Human UCB-
derived CD34+ HSCs were defrosted and resuspended in
PBS + 2% FBS, and 1 9 105 cells injected into each mouse
i.v.
Immune comparison study
To avoid donor-related fluctuations (Figure 1a), irradiated
NSG mice in the PBMC, SPMC and BM-HSC models were
reconstituted with human cells from the same adult donors
(Donors 1–3) in three independent experiments (n = 4–6 per
group). For the SPMC dKO model, irradiated NSG-dKO mice
(n = 6) were humanised with SPMCs from Donor 3. For the
UCB-HSC model, NSG mice (n = 7) were reconstituted with
UCB-HSCs cells obtained commercially (Donor 4).
Mice were monitored daily and were sacrificed if they
lost > 15% of their body weight or exhibited signs of GvHD
such as hunched posture, piloerection or reduced mobility.
Humanisation levels in mice were monitored by flow
cytometry either weekly or bi-weekly, in tail blood samples
collected in EDTA coated tubes. SPMC-reconstituted NSG-
dKO mice that did not develop GvHD were sacrificed at
20 weeks. BM-HSC and UCB-HSC reconstituted mice were
sacrificed after 20 weeks of human reconstitution, when
they showed stable engraftment of human cells in blood as
described previously11,16.
Flow cytometry
Tail blood samples were processed with RBCL buffer to
lyse erythrocytes. Human immune cell populations were
assessed using a FACSCanto II (BD Biosciences, San Jose,
CA, USA) flow cytometer and stained with specific
antibodies listed in Supplementary table 2. Data were
analysed with FCS Express Research Edition (De Novo
Software, Pasadena, CA, USA). Human cells were
phenotyped as follows: leucocytes (hCD45+/mCD45.1/
7AAD), T cells (hCD3+/hCD45+), B cells (hCD19+/hCD45+)
and monocytes (hCD14+/hCD45+).
At sacrifice, single cell suspensions were prepared from
spleen and BM of mice by mincing the spleen with the
plunger of a syringe, or by flushing the tibiae and femurs
with RPMI-1640 and filtering through a 70-µM cell strainer;
whole blood was also collected in EDTA coated tubes.
Erythrocytes were lysed and cells stained for
immunophenotyping of human cells with specific
antibodies listed in Supplementary table 2. Stained samples
were fixed with 2% paraformaldehyde, then washed and
run on a FACSymphonyTM flow cytometer (BD Biosciences),
acquiring at least 30000 hCD45+ events. Data were analysed
with FCS Express Research Edition. Human cells were
phenotyped as follows: leucocytes (hCD45+/mCD45.1/
FVD), T cells (hCD3+/hCD45+), B cells (hCD19+/hCD45+),
monocytes (hCD14+/hCD45+), macrophages (hCD206+/
hCD45+) NK cells (hCD56+/hCD45+), Dendritic cells (hCD11c+/
HLA-DR+/hCD14/hCD45+), T memory cells (hCD45RO+/
hCD3+), na€ıve T cells (hCD45RA+/hCD3+), CD4+ T cells
(hCD4+/hCD3+), Th1 (hCXCR3+/hCCR5+/hCD4+), Th2 (hCCR4+/
hCCR6/hCD4+), Th9 (hCCR4/hCCR6+/hCD4+), T follicular
helper (TFH) (hCXCR5+/hCD4+), Treg (hCD25Hi/hCD127Low/
hCD4+), CD8+ T cells (hCD8+, hCD3+), Tc1 (hCXCR3+/hCCR5+/
hCD8+) and Tc2 (hCCR4+/hCCR3+/hCD8+). Multidimensional
data were represented using vi-SNE and FlowSOM on the
Cytobank platform (Beckman Coulter, Brea, CA, USA). vi-
SNE method was run processing 30 000 hCD45+ cells and
setting the following parameters: iterations = 1000,
perplexity = 30.
Histology
All tissues were fixed in 10% neutral buffered formalin
(Leica Biosystems, Wetzlar, Germany), processed and
embedded into paraffin wax. Tissue sections (4 µm thick)
were stained with haematoxylin & eosin (H&E). Additional
serial sections were immunohistochemically stained for
hCD45 (clone D9M8I, Cell Signaling Technology, Leiden, The
Netherlands) and hCD3 (clone CD3-12, Bio-Rad, Watford,
UK), using the automated staining platforms Leica Bond RX
(Leica Biosystems) and Autostainer Link 48 (Dako Agilent,
Santa Clara, CA, USA). The hCD45 IHC protocol had
previously shown specificity for human cells, with absence
of staining when applied to normal mouse lymphoid tissues
(unpublished observations). Microscope slides were digitally
scanned (Aperio, Leica Biosystems) to obtain whole slide
scans. Sections stained with hCD45 were analysed for
amount of positive staining using Halo image analysis
software (Indica Labs, Albuquerque, NM, USA). Positive
hCD45 staining was reported as % positive area over total
tissue area.
Cytokine production, activation and
proliferation in vitro
Single cell suspensions from the spleen of humanised mice
were prepared in RPMI-1640 medium as described above.
Human mononuclear cells were isolated by gradient
centrifugation on LymphoprepTM at 800 g, for 20 min, at RT
and cryopreserved in liquid nitrogen. Analysis for cytokine
release and proliferation of the cells in vitro was performed
according to the methods described by Stebbings et al.
200757. Briefly, 1 µg of the therapeutic mAb OKT3 (murine
IgG2a, anti-CD3, Tonbo Biosciences, San Diego, CA, USA)
was wet coated in duplicates directly on 96-well round
bottom polypropylene plates (Corning). CD3/CD28
Dynabeads (Gibco) were used as positive control and
added in duplicates into the wells to give a bead:cell ratio
of 1:4. Non-treated wells were used as negative controls.
For cytokine release analysis, the isolated human cells were
defrosted and washed, then 2 9 105 cells were added into
the wells and incubated for 20 h in a humidified incubator
at 37°C with 5% CO2. The secretion inhibitor Brefeldin A
(Thermo Fisher Scientific, Paisley, UK) was added to the
wells at 10 µg mL1 for the last 4 h of incubation.
Intracellular cytokine production was measured by flow
cytometry in a FACSCanto II instrument acquiring 20000
hCD3+ events.
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For measuring T-cell proliferation, the isolated human
cells were labelled with CellTraceTM CFSE (Thermo Fisher
Scientific), according to the manufacturer’s instructions and
plated at 2 9 105 cells/well into the 96-well round bottom
plates prepared as mentioned above. Cells were incubated
for 72 h in a humidified incubator at 37°C with 5% CO2.
Cells were stained with specific human antibodies listed in
Supplementary table 2. Activation and proliferation of T
cells was measured by acquisition of 20000 hCD3+ cells by
flow cytometry in a FACSCanto II instrument and cells
phenotyped as follows: activated T cells (hCD25+/hCD3+/
hCD45+), proliferating T cells (CFSELow/hCD3+/hCD45+). Data
were analysed with FCS Express Research Edition.
OKT3 toxicity study
NSG mice were irradiated and subsequently humanised, as
stated above, with either PBMCs (n = 6 or 7 per group),
SPMCs (n = 8 or 9 per group) or BM-HSCs (n = 5 or 6 per
group) from the same adult donors (Donors 5 and 6) or
with commercially obtained UCB-HSCs cells (Donor 4) (n = 6
or 7 per group), in two independent studies. Additionally,
irradiated NSG-dKO mice (n = 8) were humanised with
SPMCs from Donor 6 (Figure 6a). Human lymphocyte
engraftment levels were monitored over time as described
above. Only mice with a minimum of 100 hCD3+ cells per µL
of whole blood were enrolled in the experiment before the
onset of GvHD. These levels were reached at different times
among the distinct humanised mouse models. At that
point, blood was collected in EDTA coated tubes, and body
temperature was measured using an infrared thermometer
(Bokang, Wenzhou, China) before treatment. OKT3 (anti-
CD3) was subsequently administered i.v. via tail vein at a
final concentration of 2 mg kg1, diluted up to 100 µL with
PBS. This concentration corresponds to a 1.95-fold the
dosage used in patients during the clinical trial.9,58 Mice in
the control groups were injected i.v. with 100 µL of PBS.
Animals were monitored for the following 6 h to evaluate
the appearance of clinical symptoms. Body temperature of
mice was measured again just before experiment
termination at 6h. Total blood was collected in EDTA
coated tubes at sacrifice, and tissues retrieved. To
determine absolute cell counts peripheral blood was
directly stained with specific antibodies listed in
Supplementary table 2. Erythrocytes were lysed with RBCL
buffer and Absolute Counting Beads (CountBrightTM,
Thermo Fisher Scientific) were added prior to analysis on a
FACSCanto II. Single cell suspensions from the spleen of
humanised mice were prepared in RPMI-1640 medium,
stained as described above and analysed on a FACSCanto II.
Data were analysed with FCS Express Research Edition.
Human cells were phenotyped as follows: leucocytes
(hCD45+/mCD45.1/7AAD), B cells (hCD19+/hCD45+), T cells
(hCD3+/hCD45+), TCR a/b complex (hTCR a/b
+/hCD45+), CD4+
T cells (hCD4+/hCD3+) and CD8+ T cells (hCD8+/hCD3+).
Cytokine quantification
Human cytokines in plasma were measured using the
Human cytokine Th1/Th2/Th17 Cytometric Bead array kit
(BD Biosciences), which includes analytes for the detection
of 7 human cytokines: IL-2, IL-4, IL-6, IL-10, TNF, IFN-c and
IL-17A. Mouse plasma was recovered from total blood
samples and stored at 80°C until used. Plasma samples
were prepared following the manufacturer’s instructions
and analysed on a FACSCanto II instrument.
Statistical analysis
Littermate animals were randomly assigned to control or
treatment groups, and data were analysed blinded to the
group identity. GraphPad Prism 8 (GraphPad Software, San
Diego, CA, USA) was used for data analysis. To assess
statistical differences between two independent groups, we
used the non-paired t-test. Differences before-after in the
same group were analysed with the paired t-test.
Comparisons between multiple datasets were assessed using
a two-way ANOVA followed by the Tukey’s multiple
comparisons test. For survival analysis, Kaplan–Meier plots
were represented and statistical differences calculated using
the Mantel–Cox test.
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